Clinical Trials Logo

Clinical Trial Summary

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV status using Chartis Pulmonary Assessment System. Subjects with CV- status will then undergo placement of Zephyr Valve in the target lobe for bronchoscopic lung volume reduction (BLVR) and be followed for 24 months.


Clinical Trial Description

This is a multicenter, prospective, single-arm, pivotal trial with a 24-month follow-up to evaluate the safety and effectiveness of the AeriSeal System to block CV. The study plans to enroll up to 200 subjects at up to 30 clinical centers in US and OUS. Study subjects will be patients with severe, heterogeneous emphysema and collateral ventilation in the lobe targeted who are candidates for BLVR. Subjects meeting initial eligibility will undergo a bronchoscopy procedure under general anesthesia during which the presence of CV will be confirmed using Chartis. All enrolled subjects meeting final eligibility will undergo the AeriSeal procedure. Conversion of collateral ventilation status from CV+ to CV- in the target lobe will be evaluated by Chartis at Day 45 post-AeriSeal treatment (primary effectiveness endpoint). All subjects not converted from CV+ to CV- status will undergo a repeat of the AeriSeal procedure, provided that the total volume from both the initial and the repeat treatments does not exceed 40 mL in up to 3 segments. All subjects converted from CV+ to CV- status after either the index or repeat AeriSeal procedure will undergo BLVR with Zephyr Valve per standard of care in accordance with the approved instructions for use and will be followed through Month 24 (end of study). All CV+ subjects who remain CV+ after the repeat procedure or do not undergo the repeat AeriSeal procedure will be followed through Month 24 (end of study). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06035120
Study type Interventional
Source Pulmonx Corporation
Contact Christina Kutzavitch, PhD
Phone +1 650-216-0134
Email ckutzavitch@pulmonx.com
Status Recruiting
Phase N/A
Start date February 22, 2024
Completion date March 31, 2028

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Recruiting NCT03285100 - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation N/A
Not yet recruiting NCT05900544 - Maximizing Benefit of Lung Cancer Screening Incidental Findings of Cardiovascular, Respiratory and Breast Measures N/A
Recruiting NCT06163131 - The Effect of Treatment of Emphysema With Endobronchial Valves on the Diaphragm Mobility
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT05854550 - First in Human Study to Assess an Implant to Treat Severe Emphysema N/A
Recruiting NCT05257681 - Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction N/A
Recruiting NCT06068647 - Ultrasound and Respiratory Physiological Signals in Lung Diseases N/A
Recruiting NCT03318406 - Post-Market BTVA Registry
Recruiting NCT04214587 - Biological Investigation of Explanted Endobronchial Lung Valves Study
Completed NCT03205826 - Chartis Collateral Ventilation Measurement: Conscious Sedation Versus General Anesthesia N/A
Recruiting NCT04781582 - LVRS Versus BLVR in Patients With Homogenous Emphysema, CLUB-HE Trial N/A
Completed NCT04520152 - Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema N/A
Recruiting NCT03680495 - Steroid Resistance During COPD Exacerbations With Respiratory Failure
Active, not recruiting NCT04517916 - Zephyr Etude Post-Inscription (French Registry)
Recruiting NCT06249529 - Airway Bypass - Safety and Feasibility Study Early Phase 1
Recruiting NCT05567562 - Anti-Platelets in Chronic Obstructive Pulmonary Disease Phase 2
Withdrawn NCT04029077 - Introduction of the Vapor Treatment in The Netherlands
Recruiting NCT03755505 - The Microbiome of Sputum, Urine and Feces in Healthy Persons and Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed NCT03670121 - A Pilot Study to Assess Treatment of Patients With Homogeneous Emphysema Using Sequential Segmental Bronchoscopic Thermal Vapor Ablation (NEXT STEP) N/A